Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1997
|
| gptkbp:ATCCode |
J01DD15
|
| gptkbp:bioavailability |
21%
|
| gptkbp:CASNumber |
91832-40-5
|
| gptkbp:color |
white to slightly yellowish powder
|
| gptkbp:contraindication |
patients with known allergy to cephalosporins
|
| gptkbp:drugClass |
gptkb:antibiotic
cephalosporin |
| gptkbp:excretion |
renal
|
| gptkbp:generation |
cephalosporin
|
| gptkbp:halfLife |
1.7 hours
|
| gptkbp:hasChEMBL |
CHEMBL1173
|
| gptkbp:hasInChIKey |
QYURTLLQXLPFHB-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C14H13N5O5S2
|
| gptkbp:hasSMILES |
COC1=CC=C(C=C1)C2=NC3=C(C(=O)N2)N(C(=O)CS3)C(=O)O
|
| gptkbp:hasUNII |
9Q1OE8U6S5
|
| https://www.w3.org/2000/01/rdf-schema#label |
DB04868
|
| gptkbp:indication |
gptkb:sinusitis
bronchitis tonsillitis treatment of bacterial infections otitis media pharyngitis community-acquired pneumonia skin and skin structure infections |
| gptkbp:legalStatus |
expired
prescription only |
| gptkbp:manufacturer |
gptkb:Abbott_Laboratories
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:meltingPoint |
>200°C
|
| gptkbp:metabolism |
not significantly metabolized
|
| gptkbp:molecularWeight |
395.414
|
| gptkbp:name |
Cefdinir
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
60-70%
|
| gptkbp:PubChem_CID |
gptkb:DB04868
3494 606378 D00251 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache rash vaginal moniliasis |
| gptkbp:solubility |
slightly soluble in water
|
| gptkbp:status |
true
|
| gptkbp:synonym |
Cefdinirum
Omnicef |
| gptkbp:target |
penicillin-binding proteins
|
| gptkbp:bfsParent |
gptkb:nilotinib
|
| gptkbp:bfsLayer |
6
|